| 08:00 |
Congress Registration Open - All Day |
| 09:00 - 12:00 |
SYMPOSIUM Terapeutic Apheresis in Japan at thefront
(Sponsored Symposium by Asahi Kasei-Kuraray Medical Co.Ltda)
Chair: Noritoshi Shibuya, Koga Hospital Group, Fukuoka
Hiroshi Tsuda, Juntendo Tokyo Koto Geriatric Medical Center"
|
| 0900 - 0930 |
Cardiodepressant IgG3 autoantibody elimination by immunoadsorption in patients with dilated cardiomyopathy -Akiyasu Baba |
| 0930 - 1000 |
Novel therapeutic strategy for chronic hepatitis C- Double filtration plasmapheresis and (PEG) interferon/ribavirin combination therapy - Tatsuya Ide. |
| 1000 - 1030 |
Leukocytapheresis as a therapeutic option for intractable inflammatory bowel disease. Takayuki Matsumoto |
| 1030 - 1100 |
Coffee Break |
| 1100 - 1130 |
Therapeutic apheresis in the neurological disorders - Kyoichi Nomura |
| 1130 - 1200 |
Therapeutic apheresis for rheumatic disease - Ken Yamaji |
| 1200 - 1300 |
Poster session and Lunch |
| 1300 / 1800 |
Registries + Regulatory + Reimbursement |
| 1300 - 1500 |
Registries: Chair: B. Stegmayr and P. Malchesky |
| 1300 - 1330 |
The Canadian data 1980- up
Chair: Gail Rock,MD. Canadian Apheresis Group |
| 1330 - 1500 |
Registries + regulatory Issues/ Reimbursement (ISFA) |
| 1330 - 1400 |
World Apheresis Registry - current status - B. Stegmayr |
| 1400 - 1430 |
International Survey on Apheresis Therapy-Update - P. Malchesky |
| 1430 - 1500 |
Data from the Hungarian Hemapheresis Registry - M.Belak |
| 1500 - 1530 |
Coffee Break |
| 1530 - 1800 |
Regulatory Issues / Reimbursement: Chair: P. Ivanovich and W. Ramlow |
| 1530 - 1600 |
Indications and reimbursement for apheresis therapy in
Japan - Tani/Endo |
| 1600 - 1630 |
Coverage for Apheresis treatment in the US - F.Siami |
| 1630 - 1700 |
“Indications and reimbursement for Apheresis in Argentina”
M.A.Figueroa - H.Gonzalez |
| 1700 - 1730 |
Harmonization of study protocols for apheresis treatment a never ending story?- W. Ramlow |
| 1730 - 1800 |
Round Table |
| 1800 - 1830 |
WAA - ISFA Opening Ceremony |
| 1830 - 2000 |
Honor Wine |
| 0800 - 1230 |
Cardiovascular diseases I and II |
| 0800 - 1000 |
Cardiovascular diseases I: Chair: Schuff - Werner. |
| 0800 - 0830 |
LDL cholesterol and Lp(a) - significant independent risk
factors for the devolepment of atherosclerosis- H.-U. Kloer |
| 0830 - 0900 |
Long-term benefit of LDL apheresis - P. Schuff-Werner |
| 0900 - 0930 |
Update on LDL apheresis in the US - P. Moriarty |
| 0930 - 1000 |
Immunoadsorption in idiopathic dilated cardiomyopathy -
L. Herda |
| 1000 - 1030 |
Coffee Break |
| 1030 - 1230 |
Cardiovascular diseases II: Chair: P. Moriarty and
H.U. Kloer |
| 1030 - 1100 |
Lp(a)-Apheresis: does it really work? - A. Vogt |
| 1100 - 1130 |
Specific Lp(a) Apheresis, Who, When and How? - S.N Pokrovvsky |
| 1130 - 1200 |
Positive Rheological effects of apheresis - A. Ramunni |
| 1200 - 1230 |
Apheresis therapy in acute ischemic stroke - J. Xue |
| 1230 - 1400 |
ISFA BOARD MEETTING |
| 1200 - 1400 |
Poster session and Lunch |
| 1300 - 1400 |
Apheresis New Technology |
| 1300 - 1330 |
Comparison of pathogen inactivation plasma for use in plasma exchange
Chair : Gail Rock,MD.
|
| 1330 - 1400 |
New machine, our experience Beata J. Kwiatkowska |
| 1400 - 1730 |
Autoimmune Diseases I and II |
| 1400 - 1520 |
Autoimmune Diseases I: Chairs: J. Emmrich and T. Matsumoto.- |
| 1400 - 1420 |
Apheresis therapy in inflammatory bowel diseases- Were do we stand? - J. Emmrich |
| 1420 - 1440 |
Activated blood cells' removal as a potential marker to predict clinical efficiency of leukocytapheresis for inflammatory bowel disease( IBD) patient -
K. Fukunaga |
| 1440 - 1500 |
Immunoadsorption and autoimmunoadsorption in autoimmune bollus skin diseases - E. Schmidt |
| 1500 - 1520 |
Selective immune apheresis in rheumatoid arthritis. -
H. Prophet |
| 1520 - 1530 |
Questions |
| 1530 - 1600 |
Coffee Break |
| 1600 - 1730 |
Autoimmune Diseases II: Chairs: G. Siami and K. Derfler |
| 1600 - 1620 |
Therapeutic apheresis for renal disease - A. A. Kaplan |
| 1620 - 1640 |
Long term improvement in the disability of worsening mielo sclerosis (MS) patients with plasma exchange: Results of a 25 year follow up study. - B.O. Khatri |
1640 - 1700 |
Sustained improvement in the disability of neuromyelitis optica (NMO) patients with long term plasma exchange. - BO Khatri |
| 1700 - 1720 |
Plasma Exchange in vasculitis- W. Szpirt |
| 1720 - 1730 |
Questions |
| 1730 - 1900 |
Apheresis Donors and Hemovigilance |
| 1730 - 1750 |
Apheresis Donors - M. Lozano |
| 1750 - 1810 |
Sociological and anthropological aspects in blood donor motivation - Mauro Cesar de Andrade. |
| 1810 - 1830 |
Alternatives in the blood transfusion - Alana M. de Castro. |
| 1830 - 1850 |
Hemovigilance – Dra. Youko Nukui |
| 0800 – 0920 |
Septic shock and liver failure.
Chair: A. A. Kaplan and Y.Endo |
| 0800 - 0820 |
The role of apheresis therapy in septic shock and liver failure - D.Falkenhagen - |
| 0820 - 0840 |
Extracorporeal albumin dialysis- a japanese perspective - T. Abe |
| 0840 - 0900 |
Cytokine removal by apheresis techniques in the critically ill –Y. Endo |
| 0900 - 0920 |
Discussion |
| 0920 - 1020 |
Transplantation
Chair: H. Klinkmann and T. Tani |
| 0920 - 0940 |
Extracorporeal photopheresis in Graf vs Host disease in allogenic bone marrow transplantation
J. Fernandez, |
| 0940 - 1000 |
Immunoadsorption in HLA - presensitized kidney trasplant recipients. - K. Defler |
| 1000 - 1020 |
Specific immunoadsorption in ABO incompatible kidney transplantation - H. Genberg |
| 1020 – 1040 |
Coffee Break |
| 1040 - 1100 |
Thrombotic Microangiopathy
Chair: G. Rock - D. Riveros |
| 1040 - 1100 |
Thrombotic thrombocytopenic purpura and HUS (ttp/hus) - Gail Rock |
| 1100 - 1120 |
Rituximab Therapy of TTP: Rationale for the NIH-Sponsored STAR Trial - Ronald Strauss |
| 1120 – 1240 |
Pediatric Apheresis.
Chair : Ana Maria Pugliese – Diego Fernandez Sasso |
| 1120 - 1140 |
Open questions in pediatric apheresis. - Volker Witt |
| 1140 – 1200 |
Apheresis system for very small children - Volker Witt
|
| 1200 – 1220 |
Indication of plasma exchange and IGIV in immunized heart transplantation. - Samir Saheb |
| 1230 - 1330 |
Lunch |
| 1330 / 1530 |
SYMPOSIUM Cell Therapy , “ Cell Therapy to the XXICentury"
Chair: E. Novoa- B. Koziner – A. Rodriguez
|
| 1330 - 1350 |
Diabetes & Regenerative Medicine - M.Soto Valdez |
| 1350 - 1410 |
Left ventricular function and cell therapy - Benetti |
| 1410 - 1430 |
Amyotrophye lateral sclerosis and cell implantation - A.Córdoba |
| 1430 - 1450 |
Dendritic Cells vaccines and T-cells.- Dr. Gunnar Kvalheim |
| 1450 – 1510 |
Therapy angionenesis by autologus bone marrow
transplantation in arterial limb ischaemia E. Novoa
Amyotrophye lateral sclerosis and cell implantation - A.Córdoba
|
| 1510 – 1530 |
Cell Therapy today and future - B. Koziner |
| 1530 - 1600 |
Coffee Break |
| 1600 – 1800 |
Bone Marrow Transplantation (BMT):
Hematopoietic stem cells collection and transfusion medicine support. |
| 1600 – 1620 |
Hematopoietic progenitor cells collection - M. Lozano |
| 1620 - 1640 |
Prophylactic platelet transfusions: considerations for
the pretransfusion trigger and dose/number of platelets to be given - Ronald Strauss
|
| 1640 - 1700 |
The current status of neutrophil / granulocyte transfusions for infected neutropenic patients - Ronald Strauss |
| 1700 - 1730 |
Hematopoietic stem cells collection in pediatric patient - Beata J. Kwiatkowska |
| 1730 - 1750 |
Hematopoietic stem cells collection in pediatric patients with low weight - Chair: Mario Figueroa – D. Fernandez Sasso. |
| 1750 - 1800 |
Discussion |
| 1800 - 1830 |
WAA-ISFA CLOSING CEREMONY.
|
| 21:00 |
Dinner & Show
|
